On European Multiple Myeloma Day, research and quality of life: remember who we are fighting for
Approximately 50% of patients with multiple myeloma experience a significant decline in their quality of life, particularly regarding their physical and emotional well-being. At Oncopeptides, we believe that the quality of life of people with multiple myeloma in particular, and with hematological cancers in general, is clearly an unmet need—a need that treatments must address and that requires further research
